New ZOSTAVAX commercial will
heighten awareness of Shingles vaccine
Be prepared for patient enquiries
THINGS TO KNOW BEFORE USING ZOSTAVAX (zoster virus vaccine, live)
19,400 PFU as 0.65 mL vial for injection:
Indications: for immunisation of individuals 50 years of age or older for the prevention of herpes zoster (shingles), the prevention of postherpetic neuralgia (PHN) and the reduction of acute and chronic zoster-associated pain. Contraindications: patients who are hypersensitive or allergic to any vaccine component including gelatin or neomycin; have a primary or acquired immunodeficiency state or condition; are receiving immunosuppressive therapy; have untreated tuberculosis; are or may potentially be pregnant. Pregnancy should be avoided for 3 months following vaccination. ZOSTAVAX is not recommended for paediatric use, nursing mothers, or those with a fever, epinephrine should be available in case of anaphylactic reaction. Common side effects are: headache, localised injection site reactions and pain in the arm or leg. ZOSTAVAX is a private purchase prescription only medicine that the patient will need to pay for. For detailed prescribing information, consult the data sheet, phone 0800 500 673 or refer to the Medsafe website www.medsafe.govt.nz . Based on data sheet prepared 18/06/2014 Supplied by: Merck Sharp & Dohme (NZ) Limited, Newmarket, Auckland. VACC-1112213-0013. First Issued March 2014. TAPS DA1521MW WEL433887 03/15
All rights reserved.